Johnson & Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed "maintained improvements" over 84 weeks.
The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced "sustained reductions" in total immunoglobulin G.
Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions "confirm a safety profile consistent" with its phase 3 study, Johnson & Johnson said.
The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.
Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.
The company's shares were up 2.8% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。